Big news in the peptide world. , The FDA has scheduled a formal hearing in July to review 7 peptides including BPC 157 and TB 500 for legal compounding. , This isnt approval. But its FDA's Legislative Request on Rx and Compounded Drug Advertising Coalition for Healthcare Communication The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy